Chinese biopharma firm Antengene seeks Hong Kong listing

pills adobe stock 575x375 pharmaceuticals
By Jonathan Breen
28 Aug 2020

Antengene Corp, a clinical stage biopharmaceutical company, has set the ball rolling for a Hong Kong IPO, adding to a bulging pipeline of healthcare firms targeting the city’s bourse.

Antengene is based in Mainland China and focuses primarily on oncology, using research and development to discover and commercialise new medicines.

The firm filed a draft prospectus with the HKEX on Thursday through IPO sponsors Goldman Sachs and JP Morgan.

Healthcare is one of the few sectors to ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial